Please use this identifier to cite or link to this item: https://doi.org/10.1111/ajco.13223
Title: A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
Authors: Ng, IW
Tey, JCS 
Chia, DWT 
Yee, CM
Cheo, TST 
Keywords: lung neoplasm
neoplasm metastasis
palliative care
radiotherapy
Issue Date: 1-Jan-2019
Publisher: Wiley
Citation: Ng, IW, Tey, JCS, Chia, DWT, Yee, CM, Cheo, TST (2019-01-01). A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?. Asia-Pacific Journal of Clinical Oncology. ScholarBank@NUS Repository. https://doi.org/10.1111/ajco.13223
Abstract: © 2019 John Wiley & Sons Australia, Ltd Aim: Whole brain radiotherapy (WBRT) is commonly used to treat brain metastases (BM) from nonsmall cell lung cancer (NSCLC). Its utility is increasingly being questioned after a recent randomized trial (QUARTZ) showed that its omission did not significantly impact the survival or quality of life of their patients recruited from UK and Australian centers. We report the patient characteristics and survival outcomes of our local population in comparison with theirs. Methods: Medical records of patients who received WBRT in two tertiary hospitals over 18 months were reviewed. Characteristics and survival outcomes of patient with NSCLC receiving WBRT for the first time were evaluated. Patients with prior excision of BM or stereotactic radiotherapy were excluded. Treatment details including radiotherapy dose and use of tyrosine kinase inhibitors (TKIs) were recorded. Results: Between January 2015 and June 2016, 116 patients with NSCLC received WBRT for their BM. Their median age was 65 years (range, 36-85) and median follow-up duration was 110 days (range, 14-840). A total of 102 (88%) patients had their driver mutation tested of which 59 (58%) were epidermal growth factor receptor (EGFR) mutants. Factors predicting for better survival were female gender (P <.001), EGFR mutant receiving TKIs (P =.013), prescription of 20 Gray in five fractions (P =.003), and presence of more than four BM (P =.001). Conclusion: Our patients appear to be considerably different from those recruited into the QUARTZ trial. Further prospective studies should be done to evaluate the value of WBRT in our population.
Source Title: Asia-Pacific Journal of Clinical Oncology
URI: https://scholarbank.nus.edu.sg/handle/10635/162128
ISSN: 17437555
17437563
DOI: 10.1111/ajco.13223
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
ng2019.pdfAccepted version422.85 kBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

1
checked on Jul 5, 2020

Page view(s)

89
checked on Jul 10, 2020

Download(s)

1
checked on Jul 10, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.